Form 4: Axogen EVP Sells 13,222 Shares Under 10b5-1 Plan

Axogen's EVP & General Counsel, Marc A. Began, reported the sale of 13,222 shares of common stock at $30 per share under a pre-arranged 10b5-1 plan.

Summary

• Marc A. Began, EVP & General Counsel of Axogen, Inc. (AXGN), sold 13,222 shares of common stock.
• The transaction occurred on December 11, 2025.
• The shares were sold at a price of $30 per share.
• Following the sale, Mr. Began beneficially owns 18,285 shares of Axogen common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled sale.

Sentiment

Score: 4

Explanation: The sale of shares by a key executive, even under a pre-arranged 10b5-1 plan, can be perceived as a slight negative as it reduces their direct ownership stake in the company. However, the pre-planned nature mitigates the immediate negative signal of a discretionary sale.

Negatives

• An executive selling a significant number of shares (13,222 shares) could be perceived negatively by investors, potentially signaling a lack of confidence in the company's near-term prospects, even if executed under a 10b5-1 plan.
• The sale reduces the executive's direct ownership stake in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal, potentially impacting investor confidence.
• Management: The EVP & General Counsel's personal stake in the company is reduced.

Key Dates

Recommendation

While the sale of shares by an executive can sometimes signal a lack of confidence, this transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not necessarily indicative of new, negative information. Investors should monitor future insider activity and company performance, but this single event does not warrant a change from a 'hold' position without additional context.

Keywords

Axogen, AXGN, Insider Sale, Form 4, Marc Began, EVP General Counsel, Stock Transaction, 10b5-1 Plan